BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

98 related articles for article (PubMed ID: 17487757)

  • 1. Remission of Philadelphia chromosome-positive central nervous system leukemia after dasatinib therapy.
    Abdelhalim A; Barcos M; Block AW; Sait SN; Starostik P; Wetzler M; Wang ES
    Leuk Lymphoma; 2007 May; 48(5):1053-6. PubMed ID: 17487757
    [No Abstract]   [Full Text] [Related]  

  • 2. Systemic dasatinib fails to prevent development of central nervous system progression in a patient with BCR-ABL unmutated Philadelphia chromosome-positive leukemia.
    Frigeri F; Arcamone M; Luciano L; Di Francia R; Pane F; Pinto A
    Blood; 2009 May; 113(20):5028-9. PubMed ID: 19443672
    [No Abstract]   [Full Text] [Related]  

  • 3. Isolated central nervous system relapse in patient with blast-crisis chronic myeloid leukemia in durable complete cytogenetic remission on dasatinib treatment: pharmacokinetics and ABL mutation analysis in cerebrospinal fluid.
    Zhou HS; Dai M; Wei Y; Wang Q; Xu N; Yin C; Meng F
    Leuk Lymphoma; 2013 Jul; 54(7):1557-9. PubMed ID: 23194002
    [No Abstract]   [Full Text] [Related]  

  • 4. Dasatinib: a tyrosine kinase inhibitor for the treatment of chronic myelogenous leukemia and philadelphia chromosome-positive acute lymphoblastic leukemia.
    Steinberg M
    Clin Ther; 2007 Nov; 29(11):2289-308. PubMed ID: 18158072
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Philadelphia-negative clonal hematopoiesis is a significant feature of dasatinib therapy for chronic myeloid leukemia.
    De Melo VA; Milojkovic D; Khorashad JS; Marin D; Goldman JM; Apperley JF; Reid AG
    Blood; 2007 Oct; 110(8):3086-7. PubMed ID: 17916757
    [No Abstract]   [Full Text] [Related]  

  • 6. Dasatinib maintenance therapy after allogeneic hematopoietic stem cell transplantation for an isolated central nervous system blast crisis in chronic myelogenous leukemia.
    Nishimoto M; Nakamae H; Koh KR; Kosaka S; Matsumoto K; Morita K; Koh H; Nakane T; Ohsawa M; Hino M
    Acta Haematol; 2013; 130(2):111-4. PubMed ID: 23548721
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Dasatinib crosses the blood-brain barrier and is an efficient therapy for central nervous system Philadelphia chromosome-positive leukemia.
    Porkka K; Koskenvesa P; Lundán T; Rimpiläinen J; Mustjoki S; Smykla R; Wild R; Luo R; Arnan M; Brethon B; Eccersley L; Hjorth-Hansen H; Höglund M; Klamova H; Knutsen H; Parikh S; Raffoux E; Gruber F; Brito-Babapulle F; Dombret H; Duarte RF; Elonen E; Paquette R; Zwaan CM; Lee FY
    Blood; 2008 Aug; 112(4):1005-12. PubMed ID: 18477770
    [TBL] [Abstract][Full Text] [Related]  

  • 8. [Dasatinib is an efficient therapy for central nervous system Philadelphia chromosome-positive mixed phenotype acute leukemia].
    Lin D; Zhou C; Liu B; Lyu R; Wang J; Mi Y; Wang J
    Zhonghua Xue Ye Xue Za Zhi; 2014 Nov; 35(11):1016-7. PubMed ID: 25417882
    [No Abstract]   [Full Text] [Related]  

  • 9. [Efficacy of dasatinib in treatment of imatinib-resistant BCR/ABL positive leukemia].
    Zhu Y; Pan LQ; Qian SX; Song P; Yu H; Zhang SJ; Ge Z; Hong M; Tian T; Li JY
    Zhongguo Shi Yan Xue Ye Xue Za Zhi; 2013 Jun; 21(3):581-6. PubMed ID: 23815902
    [TBL] [Abstract][Full Text] [Related]  

  • 10. [Pharmacological properties and clinical efficacy of dasatinib hydrate (Sprycel), an anticancer drug for chronic myelogenous leukemia and Philadelphia chromosome-positive acute lymphoblastic leukemia].
    Fujii Y; Amano M; Seriu T
    Nihon Yakurigaku Zasshi; 2009 Sep; 134(3):159-67. PubMed ID: 19749489
    [No Abstract]   [Full Text] [Related]  

  • 11. NKT cell-infiltrating aseptic meningitis on the central nervous system in Philadelphia chromosome-positive acute lymphoblastic leukemia treated with dasatinib.
    Imataki O; Arai T; Yamaoka G; Matsuoka A; Uemura M
    Ann Hematol; 2014 Nov; 93(11):1935-6. PubMed ID: 24756695
    [No Abstract]   [Full Text] [Related]  

  • 12. Successful second allogeneic stem cell transplantation in second remission induced by dasatinib in a child with Philadelphia chromosome positive acute lymphoblastic leukemia.
    Millot F; Cividin M; Brizard F; Chomel JC; Méchinaud F; Guilhot F
    Pediatr Blood Cancer; 2009 Jul; 52(7):891-2. PubMed ID: 19202569
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Genetic analysis of dasatinib-treated chronic myeloid leukemia rapidly developing into acute myeloid leukemia with monosomy 7 in Philadelphia-negative cells.
    Larsson N; Billström R; Lilljebjörn H; Lassen C; Richter J; Ekblom M; Fioretos T
    Cancer Genet Cytogenet; 2010 Jun; 199(2):89-95. PubMed ID: 20471511
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Isodicentric duplication of Philadelphia chromosome as a mechanism of resistance to dasatinib in a patient with chronic myeloid leukemia after resistance to imatinib.
    Loglisci G; Breccia M; Nanni M; Mancini M; De Cuia R; Cannella L; Salaroli A; Federico V; Serrao A; Loglisci MG; Santopietro M; Alimena G
    Leuk Lymphoma; 2011 Jul; 52(7):1372-5. PubMed ID: 21463110
    [No Abstract]   [Full Text] [Related]  

  • 15. Management of Bcr-Abl-positive leukemias with dasatinib.
    Hochhaus A
    Expert Rev Anticancer Ther; 2007 Nov; 7(11):1529-36. PubMed ID: 18020922
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Presence or the emergence of a F317L BCR-ABL mutation may be associated with resistance to dasatinib in Philadelphia chromosome-positive leukemia.
    Soverini S; Martinelli G; Colarossi S; Gnani A; Castagnetti F; Rosti G; Bosi C; Paolini S; Rondoni M; Piccaluga PP; Palandri F; Giannoulia P; Marzocchi G; Luatti S; Testoni N; Iacobucci I; Cilloni D; Saglio G; Baccarani M
    J Clin Oncol; 2006 Nov; 24(33):e51-2. PubMed ID: 17114651
    [No Abstract]   [Full Text] [Related]  

  • 17. Taming of the shrew--overcoming extramedullary blast crisis in the era of the new tyrosine kinase inhibitors.
    Raanani P
    Acta Haematol; 2013; 130(2):108-10. PubMed ID: 23548690
    [No Abstract]   [Full Text] [Related]  

  • 18. Extramedullary blast crisis derived from 2 different clones in the central nervous system and neck during complete cytogenetic remission of chronic myelogenous leukemia treated with imatinib mesylate.
    Matsuda M; Morita Y; Shimada T; Miyatake J; Hirase C; Tanaka M; Tatsumi Y; Maeda Y; Kanamaru A
    Int J Hematol; 2005 May; 81(4):307-9. PubMed ID: 15914360
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Dasatinib.
    Shah NP
    Drugs Today (Barc); 2007 Jan; 43(1):5-12. PubMed ID: 17315048
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Successful management of pregnancy occurring in a patient with chronic myeloid leukemia on dasatinib.
    Kroll T; Ames MB; Pruett JA; Fenske TS
    Leuk Lymphoma; 2010 Sep; 51(9):1751-3. PubMed ID: 20629520
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 5.